#USA #San Francisco #Innovent Biologics #Ollin Biosciences #IBI324

Innovent's Partner Ollin Shares Updates on IBI324 Clinical Trials

In a groundbreaking announcement, Ollin Biosciences, a clinical-stage biopharmaceutical company, has revealed promising updates regarding its collaboration with Innovent Biologics on IBI324, a bispecific antibody aimed at treating wet (neovascular) age-related macular degeneration (wAMD) and diabetic macular edema (DME). Both conditions are leading causes of vision loss among older adults and working-age populations respectively, prompting ongoing research for effective treatments.

Ollin has recently completed the enrollment of over 150 patients for the JADE study, a Phase 1b clinical trial based in the U.S. This randomized proof-of-concept trial is particularly significant as it compares IBI324, also known by its research and development (RD) code OLN324, to faricimab—the current market leader. Results from this study, which aims to explore areas of anatomical and durability differentiation between the two therapies, are anticipated in the first quarter of 2026.

What Sets IBI324 Apart?

IBI324 is characterized by its higher potency and dose compared to existing treatments, ensuring greater efficacy in combating the diseases for which it is targeted. By dual-targeting VEGF and Ang2, it aims to enhance therapeutic outcomes, asserting its position as a potential best-in-class option for patients suffering from wAMD and DME. The smaller protein format of OLN324 allows for greater target coverage which could lead to an extended duration of treatment effect, thereby reducing the burden on patients who require frequent dosing.

Charles C. Wykoff, MD, PhD, who chairs the Research department at Retina Consultants of America and sits on Ollin's Scientific Advisory Board, highlighted the critical roles that both VEGF and Ang2 play in the vascular issues that lead to wAMD and DME. He expressed optimism about the dual targeting approach of IBI324, noting it could accomplish better anatomical results and longer-lasting control of these diseases when compared to merely VEGF inhibition.

A Milestone for Innovent and Ollin

The successful enrollment of patients in the JADE study signifies a critical milestone in the partnership between Innovent and Ollin. Dr. Lei Qian, Chief RD Officer of General Biomedicine from Innovent Biologics, remarked on the progress IBI324 has made, emphasizing the importance of this collaboration in advancing potential solutions for patients with serious vision-threatening diseases. As a next-generation treatment, IBI324 is expected to provide meaningful improvements in patient outcomes compared to existing therapies like faricimab.

Historically, the results from previous Phase 1 studies of IBI324 have shown promising vision and anatomical enhancements in patients with DME, all while maintaining a favorable safety profile. This reinforces anticipation for the upcoming results from the JADE study.

About Ollin and Innovent

Founded in 2023, Ollin Biosciences is committed to acquiring and developing innovative therapies that specifically target vision-threatening diseases. With an emphasis on creating a robust pipeline and guiding ideations in ophthalmology, the company has positioned itself to forge new paths in treatment efficacy.

On the other hand, Innovent Biologics, established in 2011, is recognized worldwide for its dedication to developing high-quality biopharmaceuticals across various disease domains including oncology, autoimmune disorders, and eye diseases. With multiple products already on the market and a strong collaboration framework with notable global healthcare entities, the company's mission underscores the significance of access to effective medicines.

As IBI324 moves through its clinical phases, both Innovent and Ollin remain committed to expediting its development and delivering a desperately needed therapeutic option to those living with debilitating vision loss. The journey ahead promises hope for many, following this innovative path toward restoring vision and improving quality of life.